Julia Mendonça Margatho

Julia Mendonça Margatho

Auto-generated profile, based on publicly available information

Julia Mendonça Margatho

Chemistry Department, Laboratory in Bioanalytical of Nanosystems, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2026 in ACS Applied Nano Materials
Verified
Journal Article
Open access
JMJulia Mendonça Margatho
Julia Mendonça Margatho
TVThiago Tiburcio Vicente
Thiago Tiburcio Vicente
JFJose Eduardo Freire
Jose Eduardo Freire
Theo PavanTheo Pavan
Theo Pavan
JCJuliana Cancino-Bernardi
Juliana Cancino-Bernardi

13 May 2026 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
PGPietra de Barros Galvani
Pietra de Barros Galvani
GFGabriela Maria Costa Ferreira
Gabriela Maria Costa Ferreira
VCValéria Maria de Oliveira Cardoso
Valéria Maria de Oliveira Cardoso
UCUalter Guilherme Cipriano
Ualter Guilherme Cipriano
AZAngélica Maria Mazuera Zapata
Angélica Maria Mazuera Zapata
JCJuliana Cancino-Bernardi
Juliana Cancino-Bernardi
Drug-resistant and multidrug-resistant tuberculosis (TB) remain major challenges to effective treatment. Given that TB arises from complex bacterial survival mechanisms, addressing this multifactorial disease requires innovative and combinatorial therapeutic approaches. Although various strategies have been employed to overcome these issues, concerns regarding therapeutic efficacy persist due to the prolonged treatment duration and high toxicity. Here, we developed photoresponsive nanocarriers coencapsulating isoniazid (INH) and rifampicin (RIF), with or without gold nanorods (AuNRs), as a multifunctional platform for laser-assisted TB therapy. AuNRs were synthesized and functionalized with PLGA-SH to enable photothermal activation and integration into polymeric carriers. The resulting systems exhibited an average size of approximately 180 nm, zeta potentials around −28 mV, particle concentrations on the order of 1011 particles mL–1, as measured by nanoparticle tracking analysis, and average encapsulation efficiencies of 90% for both drugs. In vitro, photoactivated nanocarriers significantly reduced Mycobacterium tuberculosis burden in murine alveolar epithelial (MLE-15) cells and macrophages (BMDMs), as well as in human macrophages (THP-1), without inducing cytotoxicity. TB preclinical models demonstrated that laser-triggered nanocarriers significantly reduced pulmonary bacterial load in infected mice compared with untreated groups, even at low doses. These findings demonstrate that the formulation’s therapeutic efficacy depends on photothermal activation and support its potential as an adjuvant strategy for precision, light-assisted TB treatment, thereby reducing systemic exposure and minimizing toxicity.